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Background: Major Depressive Disorder (MDD) affects more than 264 million people
worldwide. Current treatments include the use of psychotherapy and/or drugs, however
∼30% of patients either do not respond to these treatments, or do not tolerate the side
effects associated to the use of pharmacological interventions. Thus, it is important to
study non-pharmacological interventions targeting mechanisms not directly involved with
the regulation of neurotransmitters. Several studies demonstrated that transcranial Direct
Current Stimulation (tDCS) can be effective for symptoms relief in MDD. However, tDCS
seems to have a better effect when used as an add-on treatment to other interventions.
Methods/Design: This is a study protocol for a parallel, randomized, triple-blind,
sham-controlled clinical trial in which a total of 90 drug-naïve, first-episode MDD patients
(45 per arm) will be randomized to one of two groups to receive a 6-weeks of CBT
combined with either active or sham tDCS to the dorsolateral prefrontal cortex (DLPFC).
The primary outcome will depressive symptoms improvement as assessed by the
Montgomery-Asberg Depression Rating Scale (MADRS) at 6-weeks. The secondary aim
is to test whether CBT combined with tDCS can engage the proposedmechanistic target
of restoring the prefrontal imbalance and connectivity through the bilateral modulation of
the DLPFC, as assessed by changes over resting-state and emotional task eliciting EEG.
Discussion: This study evaluates the synergetic clinical effects of CBT and tDCS in
the first episode, drug-naïve, patients with MDD. First episode MDD patients provide
an interesting opportunity, as their brains were not changed by the pharmacological
treatments, by the time course, or by the recurrence of MDD episodes (and
other comorbidities).
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Trial Registration: This study is registered with the United States National
Library of Medicine Clinical Trials Registry (NCT03548545). Registered June 7, 2018,
clinicaltrials.gov/ct2/show/NCT03548545. Protocol Version 1.
Keywords: MDD (Major Depressive Disorder), study protocol, drug-naïve, tDCS (transcranial direct current
stimulation), CBT (cognitive-behavioral therapy)
BACKGROUND
Major Depressive Disorder(MDD) is widely recognized as a
staggering global healthcare challenge, as well as a potentially
lethal illness (1). The worldwide prevalence of Depression is
about 3.4% [2–6%], and mild forms of depression are the most
prevalent−13%, as compared to 4% for moderate forms and 5.1
% for severe forms of depression (2). The prevalence in females
is about 4.1% and about 2.7% in males (2). Overall, MDD is
thought to affect 264 million people worldwide, thus ranking
second in the most common causes of disability with prospects
of becoming the first by 2040 (3).
The current standard care for MDD involves the use of
psychotherapy, antidepressant medication, or a combination of
both. Despite the costs involved in these interventions, the
efficacy of such treatments may have been overestimated, with
recent data suggesting that remission rates can be as low as 23%
depending on the self-report scale used (4). Furthermore, 30% of
patients suffering from MDD still exhibit depressive symptoms
despite the appropriate psychological and pharmacological
treatments (5). In order to overcome this, several treatments are
frequently combined, usually by the use of drug augmentation
and/or combination of different drugs, which often increases
the risk of adverse effects (6). Thus, the development of
effective treatment alternatives for MDD, which includes
non-pharmacological interventions targeting mechanisms not
directly involved with the regulation of neurotransmitters, is
an urgent research priority. However, in order to do so, it
is important to understand the underlying neural mechanisms
involved in MDD.
Evidence coming from several electroencephalography (EEG)
(7–9), neuroimaging (10, 11), and neuromodulation (12–15)
studies showed that the dorsolateral prefrontal cortex (DLPFC)
is as an important area of dysfunction in depression, mainly
due its left hypo and right hyper-functioning. This inter-
hemispheric imbalance over the DLPFC has been shown to
be an indicator of lifetime MDD, or in conjunction with
depressive self-schema (i.e., an interconnected negative internal
representation of the self that has been associated to the onset and
maintenance of depressive state (16, 17) to be a predictor of a first
prospective MDD episode (18). Nevertheless, some studies failed
to show the link between decreased left frontal activation and
depression (19).
Transcranial direct current stimulation (tDCS) is a non-
invasive method of brain stimulation that is capable of
depolarizing or hyperpolarizing the neural membrane and as
such, it has been used in people suffering from depression,
by placing the anode (excitatory) over the left and the
cathode (inhibitory) over the right DLPFC, or by placing the
anode over the left DLPFC and the cathode over the right
supra-orbital region.
For instance, in one study, 64MDD patients were randomized
to 15 sessions of 2mA tDCS over 3 weeks, and tDCS was
shown to be able to decreased MDD symptoms (20). However, in
another study, not only active tDCSwas superior to sham but also
the combination of tDCS with sertraline was significantly more
effective in reducing depressive symptoms than either treatment
alone (21). Although tDCS per se showed promising results in
treating MDD, the previous trial highlights that the effects of
tDCS can be enhanced by combining it with other interventions.
Overall, tDCS seems to decrease MDD symptoms by a pooled
effect size of 0.36 (22). Moreover, according to a recent individual
patient data meta-analysis, tDCS seems to be less effective in
high-resistant patients, suggesting that tDCS may be a promising
add-on therapy to therapies such as the cognitive behavioral
therapy (CBT) (23) or cognitive control therapy (24, 25).
CBT is an empirically validated therapy for the treatment of
MDD. Several studies have demonstrated the efficacy of CTB
alone (26, 27) or as adjuvant to medication (28–30) in acute
depression. Another advantage of CBT over anti-depressant
drugs is its long-term effects, namely protecting against relapses
and recurrences after active treatments has ended (27, 31, 32).
Additionally, CBT is a well-established therapy that can restore
or normalize abnormal brain activity, namely prefrontal alpha
activity (33). Namely, an increase in left frontal brain activity after
CBT in individuals with anxiety and depression.
It is important to highlight that MDD seems to induce
profound changes in the brain, namely structural alterations
in fronto-cingulate-striatal circuits (34–36). However, and
somewhat surprisingly, first episode MDD patients have not
been extensively studied with tDCS (37, 38). These first episode
MDD patients provide an interesting opportunity, as their brains
were not changed by the pharmacological treatments, by the
time course, or by the recurrence of MDD episodes (and
other comorbidities).
PURPOSE, PRIMARY AND SECONDARY
OUTCOMES
Therefore, we propose to study the clinical and mechanistic
effects of the combination of two well-studied interventions—
CBT and tDCS—for the treatment of MDD in drug naïve
first episode patients. The primary outcome will be the clinical
effects (severity of depression/mood amelioration), as measured
by the Montgomery-Asberg Depression Rating Scale (MADRS).
Secondary outcomes will be resting state and emotional task
eliciting EEG, which will be useful simultaneously to understand
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the neural effects of the intervention, as well as potential response
predictors for future trials.
RESEARCH QUESTION, AIMS,
HYPOTHESIS
By combining two interventions that showed promising results
in MDD (CBT and tDCS), we aim to investigate the clinical
and underlying neurophysiological effects in first-episode drug
naïve MDD patients. The main research question underlying
this proposal is whether tDCS as add-on therapy to CBT in
drug naïve, first-episode MDD patients could produce greater
significant clinical improvements, as measured by the MADRS,
when compared to CBT alone. We hypothesize that the
combination of these therapies will produce a synergetic effect
in the brain, potentiating the effects of CBT and decreasing the
depressive symptomatology as assessed by the MADRS.
A secondary aim will be to perform the dose calculation
(number of sessions) required to induce a clinically significant
effect (50% decrease in the MADRS score). The underlying
hypothesis is that the combination of tDCS with CBT will
require a lesser number of sessions in order to elicit this clinical
meaningful effect.
The second major scientific question is whether these clinical
improvements will be correlated with the rebalancing of the
inter-hemispheric asymmetry of EEG alpha activity toward the
left hemisphere, as assessed by resting-state and emotional task
eliciting-EEG. Here, the hypothesis is that both interventions
(combined and alone) will reduce the inter-hemispheric alpha
imbalance, as indexed by EEG power; however, that reduction
will be more pronounced in the group that received the add-on
intervention, as compared to CBT alone.
METHODS
Trial Design, Setting and Registration
This is a parallel, randomized, triple-blind, sham controlled
clinical protocol in which a total of 90 drug-naïve, first-episode
MDD outpatients (45 per arm) will be randomized to one of
two groups: active bilateral tDCS over the DLPFC combined with
CBT or sham tDCS combined with CBT (Figure 1).
Patients will complete a 6-weeks treatment that involves 18
tDCS sessions (active or sham) and 12 CBT sessions. For the
first 2 weeks of intervention, they will receive 10 daily sessions of
tDCS (fromMonday to Friday) and 4 sessions of CBT (combined
at same time with tDCS for the first 30min, on Monday and
on Friday). They will then receive two booster sessions of tDCS
combined with CBT will be on weeks 3, 4, 5, and 6 (Figure 2B).
This study will then be organized in 3 distinct phases. Phase
1: Recruitment and baseline assessments; Phase 2: Intervention;
Phase 3: Post-treatment assessment and 6-month follow-up
(Figure 1). Once eligibility is determined and consent provided,
patients will be randomly assigned to one of the two groups in
a 1:1 allocation ratio, by the means of a list generated by an
automatic web-based randomization program.
FIGURE 1 | Overview of the Study design (tDCS, transcranial Direct Current
Stimulation; CBT, Cognitive Behavioral Therapy).
After an initial baseline assessment (visit 1) (for more details
see task 1), patients will receive 10 consecutive sessions (in
two weeks) of active or sham tDCS (2mA, 30min), and 6
sessions of CBT every other day (3 CBT sessions per week).
Patients may fail 1 or 2 sessions of tDCS and/or CBT; and in
that case, they will have the opportunity to receive the missing
session (s) in the following week. The primary outcome will be
assessed by week 2, usingMADRS. Other assessments will be also
performed by week 2, such as EEG, and other clinical measures
(see Table 1). By week 4 and 6, patients will receive additional
booster sessions of the same intervention (active or sham tDCS
followed by CBT). Patients will perform the same assessments on
week 6 (Figures 2A,B). tDCS sessions will follow the same design
previously tested by two members of our group, that showed
significant clinical effects of tDCS alone, and tDCS combined
with sertraline in moderate to severe MDD (21).
Structured CBT sessions will follow the NICE guidelines
from the National Institute for Health and Care Excellence (39).
Patients will receive a total of 12 CBT sessions administered
biweekly for 6 weeks. Mood, will be evaluated at the end of each
week, as to perform the dose calculation (i.e., number of sessions)
required to induce a clinical significant effect of at least 50%
decrease in the MADRS scores.
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FIGURE 2 | Schematic representation of the main phases of the trial. (A) Shows the timeline of assessments. (B) Details how interventions sessions will be
administered by week.
In addition to the primary outcome measure (MADRS),
secondary outcome measures will be clinical response as
measured by scores on the 17-item Hamilton Depression Rating
Scale, Beck Depression Inventory (BDI), Beck Anxiety Inventory
(BAI), clinician-rated Clinical Global Impression–Severity of
Illness scale, and quality of life (QoL). These scales will be
used at baseline, week 2, 4, 6, and follow-ups (up to 6-month
follow up).
Resting-state EGG assessments will be performed on baseline
session, on weeks 2 and 6. These assessments will allow us to
assess the neural effects of these interventions in the brain.
The Standard Protocol Items: recommendations for
Interventional Trials (SPIRIT) statement were used as a
framework for developing the study methodology for this
trial (40, 41).
Participants
A total of 90 drug-naïve, first-episode MDD outpatients (45 per
arm) will be randomized to receive either CBT combined with
active bilateral tDCS over the DLPFC or CBT combined with
sham tDCS.
Eligibility Criteria
Participants will be included in this study if they meet
the following criteria: 1) Aged 18–75 years; 2) Unipolar,
nonpsychotic MDD (DSM-V); 3) Score in the MADRS 7 and
above (mild, moderate, and severe depression); 4) Low risk of
suicide, as evaluated during the clinical interview and through
the Scale for Suicidal Ideation [Mild to Moderate SIS; (42)]; and
5) Able to sign informed consent.
Potential participants meeting any of the following criteria
will be excluded: 1) any contraindication to receive tDCS (such
as metal in the head, implanted brain medical devices); 2) any
significant or unstable neurologic or psychiatric disorder other
than MDD, such as epilepsy, Parkinson’s Disease, Dementias,
eating disorders, OCD Spectrum disorders, among others);
3) history of substance abuse within the past 6-months, 4)
Any personality disorders; or 5) any severe life-threatening
disorders or concurrent medical condition likely to worsen
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patient’s functional status in next 6-months such as; cancer, or
severe heart, kidney, or liver diseases. Participants with reported
high risk of suicide will be excluded from the study and will
be recommended to receive support from an experience and
licensed psychologist/psychiatrist. Information about local and
national institutions that provide support to cope with suicidal
behaviors and though will be provided.
A screening questionnaire that addresses the specific inclusion
and exclusion criteria will be applied to each participant
prior to the SCID-5 interview and will help to screen out
participants. Diagnosis will be performed using the Structured
Clinical Interview for DSM-5 (SCID-5) (43, 44), a widely
used semi structured clinical interview designed to evaluate
psychopathology, following the categories in the DSM 5
(Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition) for the clinical use and clinical research. Potential
participants will also answer the tDCS eligibility questionnaire
and the SIS to evaluate the likelihood of suicide attempt. Patients
with high likelihood of suicide attempt will be not included
in our study and will be recommend for psychological and/or
psychiatric intervention.
Description of the Interventions
Cognitive-Behavioral Therapy (CBT)
CBT will be performed following the structure proposed by
Beck et al. (17, 45). Each session will last 60min and will be
designed individually for each patient, according to the severity
of Depression—including behavioral activation and problem-
solving techniques. A licensed and trained practitioner will
be responsible for facilitating the self-help programme and
for reviewing progresses and outcomes during psychotherapy
sessions. A senior clinical psychologist with extensive experience
in CBT in patients with depression will supervise the clinical
work. A clinical meeting will be hosted weekly in order to
perform quality assurance of the therapeutic process.
Transcranial Direct Current Stimulation (tDCS)
tDCS will be delivered by an Eldith DC Stimulator Plus
(Neuroconn, Germany), using 25 cm2 saline-soaked electrode
sponges. Anode will be placed over the left (F3) and cathode
over the right DLPFC (F4). For the active tDCS, participants
will receive 2mA (current density = 0.80 A/m2; with 15/15 s
ramp/ramp down) for 30 min/d. For sham tDCS, patients will
receive 15 s of 2mA intensity, and 15/15 s ramp in and ramp
down, with the same montage of electrodes; however, the device
will be turned off after 45 s of active stimulation. Each tDCS
session will last about 40 min: 30min of stimulation and 10-min
of set up. tDCS sessions will be performed by a research assistant,
not involved in the CBT sessions.
Description of the Assessments
These instruments will be used at baseline, after the first 2 weeks
of intervention, at the end of the 5-weeks of biweekly sessions and
follow-up visits (up to 2 months after the intervention period) as




For the depression assessment, we will use the Montgomery-
Asberg Depression Scale (MADRS) as primary outcomes.
Criteria for the use of this clinical scale will be the same as we
previously used in Brunoni et al. (21). Secondary outcomes will
include also the clinical response (categorical variable, defined
as > 50% reduction of the baseline MADRS score), clinical
remission (categorical variable, defined as aMADRS scores≤10),
and scores on the BDI.
Secondary Outcomes
Resting state EEG and task-elicited prefrontal EEG alpha
asymmetry—Resting state EEG screening will be carried out
before the intervention (baseline), and in the end of each week
of intervention. Each screening will comprise a resting state EEG
(3min eyes open and 3min eyes closed) and a task-related EEG
data collection. The task-related screening will last about 3-min
in an open-eyes active state. For this task, we will use a facial
emotion task, with approach and avoidance facial expressions,
similar to the task used by Stewart and colleagues
EEG will be acquired using 20 channel Starstim
(Neuroelectrics, Barcelona, Spain), following the 10/20 system,
in a continuous mode at a digitization rate of 500Hz, with a
bandpass filter of 0.01–100Hz. Electrode impedances will be
kept below 5 kΩ and EOG will be recorded from two additional
bipolar channels. EEG data will be segmented into 1.5–3 s epochs
centered on subject’s responses (at least 50 epochs) using EEGlab.
Sample Size Calculation
For the sample size calculation, we assume an effect size(d) of
0.66 [upper limit for the 95% CI of the pooled effect size of tDCS
on MDD (22) that for a two-side α of 0.05 and a power of 80%,
requires a total of 76 patients (38 per group). We increased the
sample size by 15% to 45 per group to account for unexpected
factors. This sample size will be adequate to detect this magnitude
of effect.
Recruitment
The enrollment of patients will be performed mainly from our
Clinical Service at the School of Psychology, and by referral from
Primary Care Physicians. After initial referral, potential patients
with first episode MDD as primary diagnosis, will undergo the
general inclusion and exclusion criteria check list in order to
assess their potential eligibility.
We will also use social media (such as the Lab Facebook
page), as well as flyers posted in specific spaces such as clinical
settings (hospital, clinics), Universities, etc. The first screening
will be performed by a research assistant (with a clinical
Psychology degree) and the full assessment of the patient will
be done by a clinician specialized in MDD (blinded to the
study arm).
Randomization
Once eligibility and consent have been approved and obtained,
randomization will occur using the randomized list generated
by an automatic web-based randomization program. Patients








































15 day, 1, 2, 3,
and 5 months
Email / Visit 1 Visit 1 Visit 2 Visit 3-12 Visit 13 Visit 14-21 Visit 22 Visit 24 – 27
Approximate visit time 1h 30 min 30 min 1 h 50 min 30 min 50 min 30 min 30 min





Consent Informed (2 copies) X
Questionnaire eligibility for the
study
X
Questionnaire eligibility to tDCS X




The structured clinical interview
for DSM-5 (SCID-V)
X
PRIMARY AND SECONDARY OUTCOME ASSESSMENTS
The satisfaction with life scale
(SWL)
X X X X
The pittsburgh sleep quality
index (PSQI)
X X X X
State-trait anxiety inventory
(STAI-Y)
X X X X
Beck anxiety inventory (BAI) X X X X
Beck’s depression inventory
(BDI)
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will be randomly assigned to one of the two groups in a 1:1
allocation ratio. Randomization order will be kept in sealed
envelopes; therefore, patients will get their assignment according
to the order of entrance in the study. This will also ensure that
all patients and all other investigators are kept blind to this
assignment for the duration of the study (allocation concealment)
(see Figure 1, for study overview).
The randomization procedures described above will be
followed for assignment to treatment groups. Following initial
screening, during participant enrollment, a research associate
will assign them to their randomly generated treatment group,
keeping all patients and all other investigators blind to this
assignment for the duration of the study.
Blinding Procedure and Assessment
Participants, the psychologists performing the CBT, the ones
performing the assessments, as well the statistician will remain
blinded to the tDCS condition up to the end of the clinical trial,
ensuring a triple blind design. Researchers applying tDCS will
not be blinded. If a serious adverse event occurs, the Principal
Investigator (PI) will be responsible for removing the blinding
and notify the Ethics Committee within 24 h.
Blinding assessment will be performed to both participants
and researchers who assessed the outcomes.
Assessments
Eligibility and tDCS Assessments
Questionnaire to assess eligibility to participate in the study: this
questionnaire aims to evaluate inclusion and exclusion criteria
to participate in the study. It includes specific questions about
neurologic and psychiatric history, history of head injuries, drugs
use, and/or abuse, history of treatments, etc.
Side Effects Questionnaire: At each stimulation session,
patients will complete a questionnaire to evaluate potential
adverse effects of tDCS (tingling, burning sensation, headache,
neck pain, mood alterations). If any side effects are reported,
the degree of relatedness to the intervention will be assessed
on a 5-point scale. This type of adverse events questionnaire
has been used frequently in our previous tDCS studies (46–52)
including in patients with MDD. In order to further control
for changes in suicidal thoughts, we will add a specific question
for suicide that can be follow-up with the SSI, if scores are
equal to or >3.
The Structured Clinical Interview for DSM 5 (SCID 5): this is
a semi-structured clinical interview (the clinician version) that
guides the clinician step-by-step through the DSM-5 diagnosis
process. This interview will be essential to confirm the diagnosis
of first episode MDD and to evaluate for possible comorbid
psychiatric disorders (43).
Scale for suicide ideation (SSI): this is a 19-item scale that aims
to quantify and assess suicidal intention (42). Patients scoring
SSI≥6 will not be enrolled in the study (53).
tDCS blinding questionnaire: After the treatment has ended,
patients will complete a questionnaire to determine if our
blinding methods were effective. We are using a 30 s sham
montage, just as we use in our other trials, keeping the device
on the subject for the duration of the session. The tDCS blinding
questionnaire is organized in two main questions: 1. Please
answer the questions to the best of your ability: 1.1 Did you
receive: Sham Stimulation (tDCS) or Active Stimulation (tDCS);
1.2 Please, rate how confident you feel in your answer (please
check one), from 1 (not confident at all), 2, 3 (somewhat
confident), 4, to 5 (completely confident).
Demographic and Clinical Assessments
Demographics information:Wewill record information about the
demographic characteristics of the study population such as age,
gender, race, level of education, and social status.
Medication Use Log: Medication use information will be
obtained at enrollment and updated on a weekly basis, by
means of a Medication Log. Participants will record their current
medications and dosages weekly, until completion of the study.
Medication diaries are commonly used to record changes in
medication use during the study period. We will also use
the Antidepressant History Treatment Form (ATHF) to assess
treatment refractoriness.
Montgomery-Asberg Depression Scale (MADRS): For the
depression improvement assessments, we will use the MADRS
for the primary outcome. This is widely used scale for the
measurement of severity of depressive symptoms in patients with
MDD. The scale is divided into 10 items, each scored on a 0
to 6-point ordinal scale (54). The MADRS will be administered
according to a structured interview procedure that has been
empirically found to result in high inter-rater reliability scores.
Beck Depression Inventory (BDI): This self-report inventory
consists of 21 multiple-choice questions and is a widely used
method to classify depression severity (55). It assesses for the
presence of several symptoms related to depression, such as
irritability, hopelessness and decreased cognitive performance.
Physical symptoms such as weight loss and fatigue are also
included. The total time required to complete this inventory is
5 to 10 min.
Quality of Life Assessment (Short version of SF-36): The short
version of the SF-36 health survey is used as a measurement of
quality of life. It provides a profile of functional health and well-
being scores. It is also used as a psychometrical index of physical
and mental health (56).
Satisfaction with Life (SWL)—is a short and rapid 7-point
Likert scale that measures life satisfaction in the perspective
of subjective well-being. Scores in SWL have been positively
correlated with measures of mental health and also predictive of
future maladaptive behaviors such as suicide attempts (57, 58).
The Pittsburgh Sleep Quality Index (PSQI): a 19-item, self-
report measure to evaluate overall sleep quality, primarily
designed to evaluate sleep disturbance in patients with psychiatric
disorders. The PSQI evaluates sleep quality in 7 categories:
subjective sleep quality, sleep latency, sleep duration, habitual
sleep efficiency, sleep disturbances, use of sleep medication, and
daytime sleep dysfunction (59, 60).
State-Trait Anxiety Inventory (STAI-Y) – a self-report measure
is organized in two subscales: State Anxiety Scale (S-Anxiety)
wish measures the current (“right now”) presence and severity
(state) of anxiety; and the Trait Anxiety Scale (T-Anxiety) which
measures the general propensity to be anxious (trait). This
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measures focus on several domains that characterizes anxiety,
such as subjective feelings, and levels of arousal (activations of
the autonomic nervous systems). The trait subscale evaluates the
more stable aspects of anxiety (“anxiety proneness”), such for
instance worry, confidence and security (61).
Beck Anxiety Inventory (BAI): is a 21-item measure of
anxiety focusing on somatic symptoms of anxiety. Each item is
descriptive of somatic, subjective or panic-related symptoms of
anxiety. Administration of BAI takes between 5 to 10min. Since
BAI focus on a “pure” measure of anxiety such as nervousness,
dizziness, inability to relax, etc.), it helps discriminating between
depression and anxiety (62, 63).
Data Management and Access to Data
Data forms and questionnaires will be coded in a standardized
manner, and double-entered in a protected excel sheet. Personal
information and all data collect will be kept in locked cabinets
that only the principal investigator will have access. A key to
access these cabinets will be kept in a safe place with limited
access. Only researchers involved in the study and any public
health and safety authorities will have access to the data collected
in the study. Any information linking data back to the participant
will be discarded to ensure that the data are truly anonymous.
Data destruction will be conducted 5 years after the study has
ended. Data sharing will only be possible after an agreement.
The data will be stored and managed following the GDPR
in the EU. According to national regulations and the Ethics
Committee approval, no Data Monitoring Committee (DMC)
will accompany this study.
Statistical Analysis
Primary Outcome
Amixed model ANOVAs will be used to assess the clinical effects
for primary outcome measure (MADRS), with intervention as
between subject factor (active vs. sham tDCS), and time as within
subject factor (weeks 2, 4, 8, 12, and 6 months). If there are
significant baseline differences across the groups, those covariates
will be included in the analysis (such as severity, anxiety, and
quality of life). If significant main effects and/or interactions arise
from the main analysis, post-hoc analysis corrected for multiple
comparisons will be performed. If our hypothesis of prefrontal
inter-hemispheric imbalance (as assessed by alpha power EEG)
is confirmed, we will then conduct correlation analysis in order
to assess whether these brain signatures correlate to long-term
clinical effects in MDD.
Secondary Outcomes
EEG Analysis
To evaluate the degree of coupling between electrode pairs, we
will use Magnitude Square Coherence as a pairwise connectivity
measurement. For power spectrum, band power, and intraband
mean and median analysis of the EEG frequency ranges, we will
use the Fast Fourier transformation analysis, which will allow
us to determine and measure the amplitude of the predominant
EEG frequency, and properties in the time and frequency
domains. For these two EEG analysis, we will define the following
frequency bands: delta (1–4Hz), theta (4–8Hz), alpha (8–13Hz),
and beta (13–30Hz) and four frequency sub-bands: low-alpha
(9-10Hz), high-alpha (10-12Hz), low-beta (13-20Hz), and high-
beta (20-30Hz), which can be obtained by decomposing the raw
signal being generated in different areas of the brain.
Independent Component Analysis (ICA) will be used for
artifact rejection. EEG changes during task will be assessed via
task-related power (TRP)–i.e., TRP at a given electrode will
be obtained by subtracting (log-transformed) power during a
pre-stimulus reference interval from (log-transformed) power
during the task. Power estimates will be obtained by squaring
filtered EEG signals and then band power values will be
averaged for both the pre-stimulus reference period and the task
intervals. Degree of coupling between electrode pairs, will be
assessed by using Magnitude Square Coherence as a pair-wise
connectivity measurement.
Ethics and Dissemination
The trial is registered with the U.S. National Library of Medicine
Clinical Trials Registry: NCT03548545 (ClinicalTrials.gov) and
is approved by the local ethics committee—Subcomissão de Ética
para as Ciências da Vida e da Saúde (SECVS) – SECVS 174/2017.
Confidentiality
All participants will be given subject identification codes
composed by letters and numbers to which all the data will be
linked. The file records that connect each participant to their
identification number will be securely kept on University servers
during the entire period of the study, and up to 5 years the study
has ended.
Dissemination Policy
Results of this study will be published in peer reviewed
journals, and will be disseminated in national and international
conferences and in social media. In any of the dissemination
procedures, subjects will not be identified or notified about
the event.
DISCUSSION
The current study describes a protocol for a parallel randomized,
triple-blind, sham controlled clinical trial to test the synergetic
clinical and electrophysiology effects of combining cognitive-
behavioral therapy with transcranial direct current stimulation in
drug-naïve, first-episode MDD patients.
By combining two therapies that have shown promising
results in patients with MDD, we expect that the group that
received CBT combined with active tDCS will have a greater
reduction on MADRS scores, and will require lesser number of
sessions in order for the clinical outcome to be reached. This
result will have a significant impact since major depression is the
secondmost prevalent mental disorder, which is thought to affect
163 million people worldwide (64). Furthermore, in Portugal,
7% of the population is diagnosed with depression every year
(65), and suicide is responsible for more than a thousand deaths
annually (66).
Despite the fact that tDCS has some promising effects on
mood, it seems that it is in the combination of tDCS with other
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intervention that the effects are larger. For instance, in the study
of Loo et al. (67), which randomized 64 patients to 15 sessions of
2mA tDCS over 3 weeks and the study of Brunoni et al. (21),
which enrolled 120 antidepressant-free patients with moderate
and severe depression, tDCS has been shown to be effective in
MDD. Moreover, in the study of Brunoni et al. (21), not only
active tDCS was superior to sham tDCS but also the combined
tDCS/sertraline was significantly more effective than in the other
treatment groups in reducing depressive symptoms. Thus, the
effects of tDCS seem to be enhanced by the combination with
other interventions. This can be particularly important, if patient
level data is taken into consideration. In a recent individual
patient data meta-analysis (23) tDCS was shown to be less
effective in high-resistant patients. This also reinforces the need
of improving tDCS techniques so they can be effective in a
broader depressed population.
We also propose to study, as secondary aim, whether CBT
combined with tDCS can engage the proposed mechanistic
target, of restoring the prefrontal imbalance and connectivity,
by changes over resting-state and task-eliciting EEG. This trial
will help to evaluate the efficacy of this combined treatment
as compared to CBT alone and to evaluate bilateral alpha
activity over the prefrontal cortex. Thus, we also expect to
demonstrate that these interventions are able to reduce the inter-
hemispheric asymmetry of alpha EEG activity toward the left
hemisphere reported in patients with depression. We expect
that the combined intervention will induce greater asymmetry
reduction (at least 50%minimum reduction).We also expect that
this inter-hemispheric imbalance reduction will be correlated
with mood improvement.
Furthermore, this mechanistic approach is one of the main
advantages of the current proposal. For instance, the use of
EEG as an adjuvant tool to exclude neurological conditions or
to help in the diagnosis of psychiatric disorders is a common
practice in the clinical setting. Evidence of abnormal findings
are obtained in about 64 to 68% of the EEGs performed
in psychiatric patients (68). These results suggest that EEG
can be a potential technique to be used as a coadjutant for
the diagnosis and prognosis of several psychiatric conditions,
with potential reliability to guide neural-based interventions.
EEG has been shown to differentiate patients with MDD
and non-depressed healthy controls. Numerous studies have
shown that depressed individuals present an asymmetry of
EEG alpha activity toward the left hemisphere, even among
previously depressed individuals when compared to those who
have never experienced clinically significant depression (7–9).
Some studies have nevertheless failed to show the link between
decreased left frontal activation and depression (19). It has
been suggested that inconsistencies in this literature may be
the result of clinical and/or methodological differences between
laboratories, such as the inclusion or exclusion of co-morbidities
(such as anxiety disorders), gender related differences, or the
choice of EEG reference (9, 69, 70). Nonetheless, there is
robust evidence suggesting that EEG alpha asymmetry is present
among individuals with present or history of clinical depression,
or even susceptibility to develop depression in the future
(71). Additionally, alpha power asymmetry-based neurofeedback
(NFB), which aims to train patients to increase right-to-left ratio
by rebalancing the left hemisphere hypoactivation, has shown
promising results in MDD (72, 73).
The advantages of EEG in MDD go far beyond its potential
to detect differences between depressed vs. non-depressed
individuals. Namely, EEG can be used to detect changes
in the EEG patterns after interventions, and as such can
be used to determine the efficacy of the intervention or if
used also in the baseline, as an outcome predictor (74, 75).
Furthermore, EEG is a direct measure of neural activity, it
allows for chronometric sensitivity, has the potential to assess
local and network effects, it is easy to use, cheap, and non-
invasive. By using EEG, it is possible to quantify the electrical
activity over specify regions of interest (power and coherence
analysis) and, therefore, correlate with symptoms severity and
response prognostic to specific treatments. Thus, creating brain
based interventions.
These changes in EEG patterns have been used to direct
several interventions, such as tDCS or TMS, however most study
lack in the assessment of the real changes in EEG activity.
For instance, based on this neurobiological basis, the main
target for treating depressive symptoms using non-invasive brain
stimulation (NIBS) techniques, such as tDCS and TMS, have been
both the left (hypoactive) and right (hyperactive) DLPFC, by
placing anodal (excitatory) over the left and cathodal (inhibitory)
over the right DLPFC (76, 77). Using this mechanistic approach
of facilitating the activation of the left DLPFC relative to the
right, beneficial emotional, and cognitive effects in MDD were
shown emotional and cognitive effects in MDD (18, 78, 79).
Moreover, we chose to include adults with first episode of
MDD only as to increase homogeneity of our study sample and
thus increase internal validity of our findings. There are several
advantages of studying the combination of these treatments in
first episode MD drug-naive patients, as their brains were not
changed by the pharmacological treatments, by the time course
of the condition, or by the recurrence of MDD episodes (and
other comorbidities). Second, combining tDCS and CBT are two
therapies that have been shown to improve MDD. Moreover,
tDCS is a safe, of easy administration, and not expensive non-
invasive brain stimulation technique that has been shown to be
effective in neuromodulating our target mechanism (imbalance
over the DLPFC). Also, CBT is the golden standard treatment
for MDD and has also shown to be able to neuromodulate
brain structures involved in MDD. Thus, if we show that
tDCS combined with CBT produce greater significant clinical
improvements in MDD, this may reduce the global burden
of MDD (for instance, by reducing the number of therapy
sessions and the number of relapses and by producing larger
long-term effects).
Therefore, the results of this project will further provide
important insights into the mechanisms underlying MDD.
In sum, we will be able to study the mechanistic reason
underlying differences between the add-on treatment group vs.
CBT combined with sham tDCS. We chose a population that is
not very well studied, namely patients drug-naïve, first-episode
MDD with mild to moderate symptoms, because several studies
failed to show the link between decreased left frontal activation
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and depression. By using resting state EEG, it will be possible to
simultaneously understand the neural effects of the intervention,
as well as potential response predictors for future trials.
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